White lupine variety Deter 1 was developed by hybridization and repeated individually-family selection of determinant, fast-ripening, albiflorous, high-yielding forms. It is characterized by determinant growth type, leaves fall off after ripening, that, together with indehiscent beans, makes the culture high-technology for cultivation and harvesting. The variety is more resistant to soil and air drought compared to other varieties included in State Register. It sustains freezing up to -5...-6°С. It is resistant to lodging, and middling resistant to fusariose damage. Peculiarity of the variety cultivation is a possibility of sowing by both usual drill method and wide-row one with row-spacing width equal to 45 cm. To realize the yield potential (in experiments it was 46 dt/ha) the heightened density of planting before harvesting (80...90 units/sq m) is necessary, which is ensured by seeding rate 1.2 million of germinable seeds per hectare. With smaller value of this indicator it is 33...42 dt/ha, while increasing seeding rate to 1.5 m/ha insignificantly increases to 47 dt/ha, to 180 m/ha decreases to 43 dt/ha. With increasing of density of planting in two times number of seeds, forming on the plant, almost unchanged, while a mass of 1000 seeds decreased only by 8 %. The growing season of Deter 1is shorter, than that of other varieties of white lupine, which allows to use it as a precursor for winter wheat, not only in the South, but also in the northern part of Central Chernozem region. The crude protein content in seeds of Deter 1 on average over 3 years was 37.4 %, crude cellulose and fat content is about 10 %.
Background. Mastocytosis is a disease caused by proliferation and accumulation of clonal mast cells in one or more organs. It is often associated with other hematological tumors. Aggressive forms of mastocytosis (AFM) require specific therapy. In non-aggressive forms of mastocytosis (NFM) symptomatic treatment is needed. Aim. To analyze the clinical course and treatment outcomes in different forms of adult mastocytosis. Materials & Methods. The retrospective analysis was based on the records of patients who received in-person and distance consultation within the period from 11/2008 to 11/2020. The analysis of complaints in disease onset and over time was carried out using questionnaires. NFM patients received symptomatic treatment with antihistamines. To all AFM patients chemotherapy was administered. Results. The analysis includes the data of 58 patients: 39 (67.2 %) women and 18 (32.8 %) men. The median age was 40 years (range 18-79 years), the median age on diagnosis was 39 years (range 1-79 years). In all patients skin rashes were reported. The median age of the first skin manifestations was 25 years (range 0.1-70 years). In-person monitoring was conducted in 34 (58.6 %) patients, 24 (41.4 %) patients received distance consultations. Median follow-up was 56.5 months (range 3-564 months). In 8 (13.7 %) patients mastocytosis was diagnosed in childhood with the median of 9 years (range 0-15 years). The diagnosis was morphologically confirmed in 46 (79.3 %) patients. Main complaints included pruritus (67.2 %), edema and erythema response to various irritants (62 %). In 45 (77.5 %) patients NFMs were reported. The regular symptomatic treatment of 78.8 % of NFM patients consisted only of antihistamines (57.9 %), and 2 (4.4 %) patients noted poor disease symptom control. One (2.2 %) patient died of associated chronic myelomonocytic leukemia. None of NFM patients required cytoreductive treatment. AFMs were diagnosed in 13 (22.4 %) patients, 5 (38.4 %) out of them had mast cell leukemia. The indications for starting chemotherapy were cytopenia (n = 3; 23 %), extensive osteolysis (n = 7; 53.8 %), ascitic syndrome with portal hypertension (n = 6; 46.1 %). Overall survival of AFM patients was 84.6 % (n = 11) with median follow-up of 80 months (range 12-131 months). Conclusion. NFM prognosis is favorable. Antihistamines are effective in relieving complaints of most patients. Cytostatic treatment of AFM in some patients provides long-lasting antitumor response.
В статье предлагается краткий обзор двух новых книг, вышедших в свет в Санкт-Петербурге в 2021 году. Актуальность данных коллегиальных трудов обусловлена персоналиями, которым они посвящены. Герои книг – народные артисты России, профессора композитор Вадим Биберган (р. 1937) и пианист Павел Егоров (1948–2017). Это первые фундаментальные издания, в которых собраны полные материалы об их жизни и творчестве. Сборник статей «Вадим Биберган. Воспоминания. Статьи» (редактор-составитель Н. Медведева, редактор Л. Марченко; издательство Санкт-Петербургского государственного института культуры) состоит из двух частей. Первая – труды самого Бибергана. Предметы его изысканий – воспоминания об учителях (Н.Н. Позняковской, В.Н. Трамбицком и Д.Д. Шостаковиче), размышления о киномузыке как самостоятельном музыкальном жанре и об опыте своей работы в нем, анализ проблем развития оркестра русских народных инструментов. Вторая часть книги включает в себя разделы: «Портрет композитора», «Глазами учеников», «Киномузыка», «Фортепианное творчество», «Вокальная музыка», «Русский народный оркестр», «Говорят друзья и коллеги». Различные по тематике статьи в сочетании с широкой географией авторов, сгруппированные по разделам, выстраивают логичную завершенную структуру книги. Мемориальный сборник статей «Арабески судьбы. Вспоминая Павла Егорова» (редакторы-составители Т. Отюгова, Н. Качаев; издательство «Геликон Плюс») – приношение выдающемуся пианисту от учеников, коллег, друзей – всего в орбиту монографического труда попало 53 автора. Воссоздан разносторонний образ яркого исполнителя, исследователя, редактора нотных изданий, почитаемого учителя. Творческие портреты Вадима Бибергана и Павла Егорова представлены в контексте ленинградской и петербургской музыкальной культуры второй половины XX – начала XXI веков. The paper briefl y overviews two new books published in St. Petersburg in 2021. These multi-author monographs are relevant as they depict the outstanding personalities: composer Vadim Bibergan (b. 1937) and pianist Pavel Yegorov (1948–2017) — two professors and People’s Artists of Russia. These books are the first scholarly publications of complete materials about their life and work. The collection “Vadim Bibergan: Memoirs and Research Papers” (compiling editor N. Medvedeva, editor L. Marchenko; St. Petersburg State Institute of Culture Publishers) consists of two parts. The fi rst one includes V. Bibergan’s own writings: he recalls his teachers N.N. Poznyakovskaya, V.N. Trambitsky and D.D. Shostakovich, reflects on film music as a separate musical genre, shares his experience in this area, and also analyzes the development problems of the Russian folk orchestra. The second part is divided into the following sections: "Portrait of the composer", "V. Bibergan through the Eyes of His Students”, “Music for Film”, “Piano Works”, “Vocal Music”, “Russian Folk Orchestra”, “Friends and Colleagues Speak”. Thanks to the above rubrics, the thematic diversity of materials, along with the wide geography of writers, creates a very logical and complete structure of the book. The second collection “Arabesques of Fortune: Remembering Pavel Yegorov” (compiling editors N. Otyugova and N. Kachaev, Gelikon Plus Publishing House) is a tribute to the memory of the outstanding pianist from his students, colleagues and friends. In total, there are 53 contributions to this joint monograph which result in a multifaceted image of this bright performer, researcher, music editor and revered teacher. These creative portraits of Vadim Bibergan and Pavel Yegorov are presented in the context of the Leningrad and St. Petersburg musical culture of the second half of the 20th – early 21st centuries.
Background . Data from real-life clinical practice studies provide additional information on the efficacy of new antitumor therapy regimens, including in patients who meet exclusion criteria for clinical trials. Aim . To evaluate the Isaomex triplet efficacy in multiple myeloma patients in real clinical practice. Materials and methods . From 2021 to 2024, the retrospective study included 83 double refractory multiple myeloma patients from 26 centers aged 38 to 85 years (median 63), who received the Isaomex triplet. Glomerular filtration rate ˂ 60 mL/min was detected at the time of isatuximabbased triplet initiation in 18 % patients, 2 of whom were on program hemodialysis. The median of previous therapy lines was 2 (1–6). The median time from diagnosis to initiation of isatuximabbased triplet therapy was 47 months (5–203). Survival curves were constructed using the Kaplan–Meier method. Statistical analysis was performed using Statistica 10 program. Results . Isaomex triplet therapy resulted in overall and renal responses in 76 % and 61 % of cases, respectively. The median progression free survival was 13.5 months. In the group of patients who did not receive daratumumab at previous stages, the median progression free survival was significantly higher and was 28 months vs 8 months (p ˂ 0.05). Threeyear overall survival was 81 %. Discontinuation of isatuximab due to the development of adverse event was recorded in 2 cases (2 %). In the group of patients with bone plasmacytomas (n = 46), Isaomex therapy resulted in an overall response rate of 67 %; 12‑month progression free survival was 48 %, and 1‑year overall survival was 76 %. Conclusion . The results of the Isaomex triplet use in real clinical practice for the treatment of relapsed multiple myeloma showed data comparable to the ICARIA registration study on the frequency of achieving a response, duration of progression free survival and overall survival. The triplet efficiency was shown in comorbid patients, with advanced stages and those undergoing renal replacement therapy.
Secondary hemophagocytic syndrome (sHLH) is a hyperinflammatory reaction which manifests with fever, cytopenia and organ damage. possible causes of sHLH include leishmaniasis. The article describes a clinical case of sHLH in patient with visceral leishmaniasis. A female 30 years old developed hectic daily fever up to 40 °C, pancytopenia, cytolytic syndrome, hyperferritin- and hypertriglyceridemia, immunoglobulin G to capsid antigens of the Epstein-Barr virus, enlarged liver and spleen a one and a half month after returning from Spain. based on the HLH-2004 and H-Score criteria, a sHLH was diagnosed, presumably associated with the Epstein-Barr virus. Immunosuppressive treatment with dexamethasone, cyclosporin-A and etoposide was started under the HLH-2004 program. Apyrexia, reduction of splenomegaly and resolution of cytolysis were achieved. The fever resumed 20 days after the start of chemotherapy, the spleen enlarged again, and therefore a diagnostic splenectomy was performed. Morphological analysis of the removed spleen revealed leishmania. After amphotericin-B therapy, the patient recovered. Chemotherapy of sHLH led to a temporary improvement for a period sufficient to verify the diagnosis and conducting of successful treatment.
В статье проведен анализ проблемы диагностики и оказания неотложной помощи детям с острым стенозирующим ларинготрахеитом на догоспитальном этапе. Острая обструкция верхних дыхательных путей при респираторных за- болеваниях является одной из основных причин, ведущих к развитию респираторного дистресса и острой дыхательной недостаточности. В работе представлена характеристика методов диагностики и интенсивной терапии острого стенози- рующего ларинготрахеита на догоспитальном этапе. Показано преимущество ингаляционной (небулайзерной) терапии за счет достижения контролируемого терапевтического эффекта лекарственных средств в кратчайшие сроки. Ключевые слова: острый стенозирующий ларинготрахеит, небулайзерная терапия, догоспитальный этап. The authors analyze the problem of diagnostics and urgent aid to children with acute stenosing laryngotracheitis at the pre-hospital stage. Acute obstruction of upper respiratory tract is one of the main reasons leading to the respiratory distress and acute pulmonary insufficiency. In the given work one can find characteristics of diagnostic and intensive care techniques in acute stenosing laryngotracheitis at the pre-hospital stage . Advantages of inhalation (nebulizer) therapy are demonstrated as well. These advantages are possible due to the controlled therapeutic effect of medicamentous preparations in the shortest period of time . Кey words: acute stenosing laryngotracheitis , nebulizer therapy, pre-hospital stage.
